Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells $237,449.10 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Wim Souverijns sold 6,090 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $38.99, for a total value of $237,449.10. Following the completion of the transaction, the insider owned 39,021 shares in the company, valued at $1,521,428.79. This trade represents a 13.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Wim Souverijns also recently made the following trade(s):

• On Monday, September 14th, Wim Souverijns sold 20,000 shares of Pharvaris stock. The stock was sold at an average price of $39.31, for a total transaction of $786,200.00.

Pharvaris Stock Down 4.3%

Shares of PHVS stock opened at $36.37 on Friday. The business’s 50 day moving average is $35.37 and its two-hundred day moving average is $31.73. The company has a market cap of $2.38 billion, a PE ratio of -11.92 and a beta of -2.33. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $43.25.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, equities analysts expect that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. UBS Group set a $79.00 price objective on Pharvaris in a research report on Wednesday, September 9th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a report on Wednesday, September 9th. Rosenblatt Securities set a $60.00 price target on Pharvaris in a research report on Wednesday, September 9th. Royal Bank Of Canada upped their price target on Pharvaris from $52.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Finally, Wedbush increased their price objective on Pharvaris from $42.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.87.

Hedge Funds Weigh In On Pharvaris

Several large investors have recently added to or reduced their stakes in the company. venBio Partners LLC bought a new stake in shares of Pharvaris in the 2nd quarter worth approximately $160,569,809. Wellington Management Group LLP increased its position in shares of Pharvaris by 12.9% during the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after purchasing an additional 274,034 shares during the period. Commodore Capital LP raised its stake in shares of Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after purchasing an additional 29,525 shares in the last quarter. 5AM Venture Management LLC acquired a new position in shares of Pharvaris in the second quarter valued at $27,581,008. Finally, Seven Fleet Capital Management LP lifted its position in Pharvaris by 144.6% in the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after purchasing an additional 457,804 shares during the period.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.